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Abstract Prostate is the most frequent cancer in men. Prostate cancer progression is driven by
androgen steroid hormones, and delayed by androgen deprivation therapy (ADT). Androgens
control transcription by stimulating androgen receptor (AR) activity, yet also control pre-mRNA
splicing through less clear mechanisms. Here we find androgens regulate splicing through AR-
mediated transcriptional control of the epithelial-specific splicing regulator ESRP2. Both ESRP2 and
its close paralog ESRP1 are highly expressed in primary prostate cancer. Androgen stimulation
induces splicing switches in many endogenous ESRP2-controlled mRNA isoforms, including splicing
switches correlating with disease progression. ESRP2 expression in clinical prostate cancer is
repressed by ADT, which may thus inadvertently dampen epithelial splice programmes. Supporting
this, treatment with the AR antagonist bicalutamide (Casodex) induced mesenchymal splicing
patterns of genes including FLNB and CTNND1. Our data reveals a new mechanism of splicing
control in prostate cancer with important implications for disease progression.
DOI: https://doi.org/10.7554/eLife.47678.001
Introduction
Prostate is the most common male sex-specific cancer (Center et al., 2012). Prostate cancer pro-
gression is controlled by androgen steroid hormones including testosterone and its active
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metabolite 5-a dihydroxytestosterone. Androgens stimulate androgen receptor (AR) signalling in
prostate cancer cells to control transcription, including of genes that regulate the cell cycle, central
metabolism and biosynthesis, as well as housekeeping functions (Livermore et al., 2016). The roles
of both androgens and the AR in transcription have been intensively investigated. However, andro-
gens and the AR also regulate alternative pre-mRNA splicing through still largely unknown mecha-
nisms (Munkley et al., 2018; Rajan et al., 2011). This represents a very important knowledge gap:
alternative splicing patterns in cancer cells can generate protein isoforms with different biological
functions (Oltean and Bates, 2014), and is a key process in the generation of biological heterogene-
ity in prostate cancer (Rajan et al., 2009).
Androgens are also closely linked to prostate cancer treatment, with androgen deprivation ther-
apy (ADT) being the principal pharmacological strategy for locally advanced and metastatic disease.
ADT utilises drugs to inhibit gonadal and extra-gonadal androgen biosynthesis and competitive AR
antagonists to block androgen binding and abrogate AR function (Livermore et al., 2016). ADT
delays disease progression, but after 2–3 years tumours often grow again, developing castration
resistance with a median survival time of 16 months (Karantanos et al., 2013). The central role of
androgens and the AR in prostate cancer, and the poor clinical outlook of castration-resistance pros-
tate cancer (CRPCa), have made it crucially important to identify androgen-regulated target genes
and mechanisms of function –particularly those that relate to metastasis. The process of epithelial-
mesenchymal transition (EMT) plays a pivotal role in prostate cancer metastasis (Gravdal et al.,
2007; Matuszak and Kyprianou, 2011; Min et al., 2010; Saini et al., 2011; Xie et al., 2010). While
the mechanisms driving EMT in prostate cancer are poorly understood, ADT has recently been
shown to directly induce EMT in both mouse and human prostate tissue (Sun et al., 2012;
eLife digest Cancers often begin as cells that grow in connected sheets or clumps known as
epithelial cells. To spread, the cancer cells need to change into cells that can break away from the
group and move through the tissues. In prostate cancer, this process can happen years after
successful treatment, but researchers are not sure why.
Prostate cancer grows in response to testosterone. This hormone circulates around the body, and
when it goes into a cell it helps select which genes are switched on or off. Testosterone-blocking
drugs can help slow prostate cancer growth by changing this switching on and off of genes. But,
over time, some cancers become resistant to the effects of these drugs and start to spread. This
may be down to complexities in how testosterone controls gene activity.
To produce a protein, a human cell first makes a copy of the corresponding gene. This copy is
then modified, cutting and pasting different parts of the sequence (a process called ‘splicing’)
before the protein is produced. The patterns of splicing a cell exhibits depend on splicing regulator
proteins.
Testosterone can change splicing patterns in prostate cancer cells, but researchers did not know
how. To find out, Munkley et al. examined a set of genes that turn off in response to testosterone-
blocking drugs in people with prostate cancer. This revealed that testosterone controls a master
splicing regulator called ESRP2, which is normally present in epithelial cells. In prostate cancer cells
in mice, extra ESRP2 slowed tumour growth. But, although ESRP2 levels are high in human prostate
cancer cells to begin with, they drop in response to testosterone-blocking drugs. In the laboratory
grown cells, the result was a switch away from ’epithelial-like’ gene splicing patterns. Some of the
new splicing patterns correlated with better patient prognosis, but other splicing patterns might
help cancer cells to spread around the body.
These results raise the possibility that blocking testosterone may impair prostate cancer growth,
but also inadvertently prepare cancer cells to break away from tumours. A more complete
understanding of how testosterone controls splicing could help explain why some tumours initially
shrink when testosterone is blocked, but then later spread. Identifying the genes controlled by
ESRP2 may reveal new drug targets to improve prostate cancer treatment.
DOI: https://doi.org/10.7554/eLife.47678.002
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Zhifang et al., 2015). Importantly, changes in alternative splicing patterns can have dramatic effects
on EMT and on metastatic disease progression (Pradella et al., 2017).
While the mechanisms through which androgens regulate splicing control are not well under-
stood, splicing itself takes place in the spliceosome, which is a multi-component structure containing
a core of essential proteins and small nuclear RNAs (Papasaikas and Valca´rcel, 2016). Splicing inclu-
sion of alternative exons is often controlled by splicing regulator proteins that bind either to regu-
lated exons or within their adjacent flanking intron sequences (Gabut et al., 2008). The estrogen
and progesterone steroid nuclear hormone receptors control splicing via recruitment of alternative
splicing regulators (including the RNA helicases Ddx5 and Ddx17) (Auboeuf et al., 2007;
Auboeuf et al., 2004; Auboeuf et al., 2002), and by changing RNA polymerase II extension rates
and chromatin structure to affect splice site selection (Kornblihtt et al., 2009; Naftelberg et al.,
2015). Steroid hormones can also drive selection of alternative promoters to include different
upstream exons in mRNAs (Dutertre et al., 2010; Munkley et al., 2018). However, to what extent
the above mechanisms may contribute to androgen-mediated splicing is largely unknown.
We reasoned that a potential model to unify the role of androgens and the AR in transcription
and splicing control could be via transcriptional regulation of genes that encode splicing regulatory
proteins.To address this we analysed a recently described set of genes that reciprocally change
expression in response to androgen stimulation in culture and ADT in patients (Munkley et al.,
2016). Here we identify AR-mediated transcriptional control of the key splicing regulator protein
Epithelial Splicing Regulator Protein 2 (ESRP2). Importantly, many ESRP2-regulated exons switch
splicing in response to androgen stimulation. ESRP2 and its close relative ESRP1 (60% identical to
ESRP2 protein) are important regulators of epithelial alternative splicing patterns (Bebee et al.,
2015; Kalluri and Weinberg, 2009; Oltean and Bates, 2014; Valastyan and Weinberg, 2011;
Warzecha et al., 2010; Warzecha et al., 2009a; Warzecha et al., 2009b), reduced expression of
which can drive critical aspects of EMT (Hayakawa et al., 2017; Pradella et al., 2017;
Warzecha et al., 2010). Our data identify an AR-ESRP2 axis controlling splicing patterns in prostate
cancer cells, and further suggest that reduced ESRP2 levels in response to ADT may inadvertently
help prime prostate cancer cells to facilitate longer term disease progression.
Results
ESRP2 is a direct target for AR regulation in prostate cancer cells
To first gain insight into how androgens may mediate patterns of splicing control, we analysed a
recently generated dataset of genes that exhibit reciprocal expression patterns on acute androgen
stimulation in vitro versus clinical ADT (Munkley et al., 2016). While a number of genes encoding
splicing factors changed expression in response to acute androgen stimulation in vitro, ESRP2 also
showed a reciprocal expression switch between acute androgen stimulation in culture and ADT in
patients (Munkley et al., 2016). ESRP2 expression decreased following ADT in 7/7 prostate cancer
patients (Rajan et al., 2014) (Figure 1A). Furthermore, RNAseq data prepared from different stages
of LTL331 patient-derived xenografts (Akamatsu et al., 2015) showed reduced ESRP2 mRNA levels
following castration and relapse neuroendocrine prostate cancer (NEPC, Figure 1B). We similarly
analysed expression of ESRP1. ESRP1 is a close paralog of ESRP2, but was not identified in our initial
screen to identify androgen-regulated genes (Munkley et al., 2016). ESRP1 expression levels also
reduced following ADT (Figure 1A). However, ESRP1 showed less change in gene expression com-
pared to ESRP2 in patient-derived xenografts following castration or relapse NEPC (Figure 1C)
(Akamatsu et al., 2015).
Further analyses supported androgen-mediated control of ESRP2 but not ESRP1 in prostate can-
cer cell lines. Western blots detected high endogenous levels of both ESRP1 and ESRP2 proteins
within the AR positive LNCaP and CWR22 RV1 prostate cancer cell lines, as compared to the AR
negative PC3 and DU145 prostate cancer cell lines (Figure 1D and E). However, qPCR analysis
showed that while androgens activated ESRP2 gene expression in response to in AR-positive LNCaP
cells, this was not observed for ESRP1 gene expression (Figure 1F). Androgen mediated-control of
ESRP2 expression was also detected in two additional AR-expressing prostate cell lines (VCaP and
RWPE-1, Figure 1G). ESRP2 protein expression was detected 48 hr after androgen exposure, with
ESRP1 protein levels not changing over this same time-period (Figure 1H). The specificity of the
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Figure 1. ESRP2 is a direct target for AR regulation in prostate cancer cells. (A) Analysis of RNAseq data from human prostate cancer pre- and post-
androgen deprivation therapy (ADT) (Chen et al., 2018; Rajan et al., 2014) shows that there is a significant downregulation of ESRP1 and ESRP2
mRNA following ADT in all seven patients tested (p=6e-04, Mann Whitney U test). (B–C) RNAseq data from LTL331 patient-derived xenografts grown in
mice (Akamatsu et al., 2015) show a greater reduction in (B) ESRP2 mRNA levels following castration compared to (C) ESRP1 mRNA levels. (D)
Figure 1 continued on next page
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ESRP1 and ESRP2 antibodies used in these experiments was confirmed by detection of over-
expressed protein and detection of siRNA mediated protein depletion by western blot (Figure 1—
figure supplement 1).
Further experimental analyses also supported ESRP2 as an early and so likely direct target for
transcriptional control by the AR: (i) ESRP2 gene expression in LNCaP cells was rapidly induced in
response to 10 nM of the synthetic androgen analogue R1881 (methytrienolone) (Figure 1I). (ii)
Chromatin immunoprecipitation (ChIP) from LNCaP cells confirmed direct AR binding to a site within
20 Kb of the ESRP2 gene promoter that had been previously predicted from a genome-wide study
(at position chr16: 68210834–68211293 on human genome assembly hg38) (Massie et al., 2011)
(Figure 1J). The AR ChIP signal adjacent to ESRP2 was similar to that detected in parallel for KLK3
(encoding prostate specific antigen, or PSA), which is a known AR-regulated gene. (iii) Consistent
with ESRP2 regulation at physiological androgen concentrations, ESRP2 transcription in LNCaP cells
was induced over a wide range of R1881 concentrations, ranging from 1 nM to 100 nM (Figure 1K).
Each of these above data are consistent with AR-mediated regulation of ESRP2 expression levels
within prostate cancer cell lines as well as tissue.
ESRP2 and its paralog ESRP1 are highly expressed in primary prostate
tumours and inhibit tumour growth in vivo
We next monitored ESRP1 and ESRP2 expression profiles from prostate cancer patients. Meta-analy-
sis of 719 clinical prostate cancer tumours from 11 previously published studies detected significant
up-regulation of both ESRP1 and ESRP2 in 9/11 datasets (Figure 2—source data 1)
(Arredouani et al., 2009; Cancer Genome Atlas Research Network, 2015; Fraser et al., 2017;
Grasso et al., 2012; Lapointe et al., 2004; Liu et al., 2006; Luo et al., 2002; Taylor et al., 2010;
Tomlins et al., 2007; Vanaja et al., 2003; Varambally et al., 2005; Wallace et al., 2008). We
experimentally validated this meta-analysis using two independent panels of clinical samples. Real-
time PCR showed significant up-regulation of both ESRP1 and ESRP2 mRNA in (1) prostate carci-
noma relative to benign prostate hyperplasia (BPH) (Figure 2A); and (2) in nine prostate tumour
samples relative to matched normal tissue from the same patient (Figure 2B). A recent study by
Walker et al. (2017) identified a molecular subgroup of prostate cancers with metastatic potential
at presentation. Within this dataset ESRP1 was 2.76 fold up-regulated in the ‘metastatic-subgroup’
compared to the ‘non-metastatic subgroup’. Using RNA from a subset of samples from the Walker
et al. study, we confirmed significant (p<0.05) upregulation of the ESRP1 gene in primary prostate
cancer patients presenting with a metastatic biology (Figure 2C). ESRP2 gene expression did not
significantly increase in the 20 samples studied. We also used these same samples to assess if the
observed up-regulation of ESRP1 and ESRP2 could result from prostate tumours consisting of a
more pure population of epithelial-derived cells compared to matched tissue. Arguing against this
possibility, levels of E-Cadherin were not significantly increased between BPH compared to prostate
carcinoma, or between matched tumour and normal prostate tissue from patients (Figure 2—figure
supplement 1).
Figure 1 continued
Western blot analysis of ESRP2 levels in a range of prostate cancer cell lines (actin was used as a loading control). (E) Western blot analysis of ESRP1
levels in prostate cancer cell lines. (F) Real-time PCR analysis of ESRP2 and ESRP1 mRNAs in LNCaP cells grown in steroid deplete (SD) or androgen (A
+) treated conditions for 24 hr (statistical significance calculated by t test). (G) Real-time PCR analysis of ESRP2 mRNA in RWPE-1 cells grown in steroid
deplete (SD) or androgen (A+) treated conditions for 24 hr. (H) Western blots analysis of ESRP1 and 2 protein in LNCaP cells treated with 10nm R1881
(androgens) for 24 and 48 hr. (I) Quantitative analysis (real-time PCR) of ESRP2 mRNA expression over a 24 hr time course following androgen exposure.
(J) Real-time PCR analysis of AR-ChIP performed in LNCaP cells treated with 10nM R1881 for 24 hr revealed AR binding proximal to the ESRP2 gene. (K)
Induction of ESRP2 is evident in LNCaP cells treated with R1881 concentrations between 1 to 100 nM (p value of 0.029 is for the comparison between 0
nm and 10nm R1881). Statistical significances were calculated by t tests, apart from (A) which used a Mann Whitney U test, and H which used Two-way
ANOVA. Real time PCR analyses used at least three independent biological replicates (RNA prepared from separate samples), apart from the AR ChIP
(panel I) for which each value shown is a mean of 3 technical replicates.
DOI: https://doi.org/10.7554/eLife.47678.003
The following figure supplement is available for figure 1:
Figure supplement 1. Confirmation of the specificity of antibodies against ESRP1 and ESRP2.
DOI: https://doi.org/10.7554/eLife.47678.004
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Figure 2. ESRP2 and its paralog ESRP1 are highly expressed in primary prostate tumours. (A) Real-time PCR analysis of ESRP1 and ESRP2 mRNA from
patients with benign prostate hyperplasia (BPH) and 17 malignant samples from transurothelial resection of the prostate (TURP) samples. (B) Real-time
PCR analysis of ESRP1 and ESRP2 mRNA from normal and matched prostate cancer tissue from nine patients obtained from radical prostatectomy. (C)
Analysis of ESRP1 and ESRP2 mRNA levels in samples from the Walker et al. (2017) cohort. Statistical analysis in parts (A)-(C) were performed using t
tests. (D) Interrogation of the TCGA PRAD (PRostate ADenocarcinoma) cohort using KM-express (Chen et al., 2018). ESRP1 expression levels linked to
Figure 2 continued on next page
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Each of the above data showed that ESRP1 and ESRP2 expression levels are relatively high in pri-
mary prostate cancer compared to normal prostate tissue. High ESRP2 expression was not prognos-
tic of disease progression in the TCGA (PRostate ADenocarcinoma) PRAD cohort analysed using
KM-express (Chen et al., 2018), but high expression of ESRP1 associated with a significantly
reduced time to first biochemical recurrence (p=0.022) (Figure 2D). We tested our antibodies
against ESRP1 and ESRP2 proteins on prostate cancer FFPE tissue and cell blocks, but they did not
pass our stringent quality control tests (Figure 1—figure supplement 1C). While this manuscript
was in preparation, another group used an alternative ESRP1 antibody to show up-regulation of
ESRP1 in 12,000 prostate cancer tissue microarray tumours (Gerhauser et al., 2018).
We next investigated the effects of ESRP1/2 expression on the biology of prostate cancer cells in
vivo. Because of their low normal endogenous expression profiles (Figure 1C and D), we selected
PC3 and DU145 cells to study the effects on prostate cancer cells of ESRP1/ESRP2 protein up-regu-
lation. Ectopic expression of ESRP1 and ESRP2 protein expression in AR negative PC3 and DU145
cell line models reduced prostate cancer cell growth in vitro (Figure 2—figure supplement 2).
Over-expression of both ESRP1 and ESRP2 (either alone or together) in PC3 cells also significantly
slowed growth of prostate cancer xenografts in vivo (Figure 2E–G). Taken together, the above data
show that ectopic expression of ESRP1 and ESRP2 proteins slow the growth of PC3 and DU145 pros-
tate cancer cell lines and are strongly suggestive that high levels of ESRP2 protein inhibit growth of
prostate cancer cells.
Identification of endogenous ESRP1/ESRP2-regulated targets in
prostate cancer cells
To enable us to test whether androgens may control splicing indirectly via transcriptional regulation
of ESRP2, we next set out to identify a panel of endogenous ESRP2-responsive exons within prostate
cancer cells. We first used siRNAs to jointly deplete both ESRP1 and ESRP2 proteins from LNCaP
cells (since ESRP1 and ESRP2 can regulate overlapping targets); and in parallel treated LNCaP cells
with a control siRNA. We then used RNAseq to monitor the effects of these treatments on the
LNCaP transcriptome. Bioinformatic analysis (Trincado et al., 2018) of these RNAseq data
(GSE129540) predicted 446 ESRP1/ESRP2 regulated alternative splicing events across 319 genes
(DPSI > 10%, p<0.05) (Figure 3—source data 1). We experimentally validated splicing switches for
44 predicted ESRP1/ESRP2-controlled exons by RT-PCR analysis, after LNCaP cells were treated
with either of two independent sets of siRNAs directed against ESRP1 and ESRP2 or control siRNAs
(Figure 3 and Figure 3—source data 2). We detected similar splicing switches for 35/44 of these
skipped exons after jointly depleting ESRP1 and 2 from the AR-positive CWR22 RV1 prostate cancer
cell line. 28/44 of these splicing switches were also observed after jointly depleting ESRP1 and
ESRP2 from the AR positive PNT2 cells that model the normal prostate epithelium (Figure 3 and Fig-
ure 3—source data 2).
Given this set of endogenous target exons, we carried out further analyses to next identify target
exons that respond to increasing levels of either ESRP2 or ESRP1 expression in PC3 cells (which nor-
mally express low levels of endogenous ESRP1/ESRP2) (Figure 1D and E). Ectopic expression of
either ESRP1 or ESRP2 in PC3 cells induced splicing switches for 31/42 exons analysed. Importantly,
Figure 2 continued
a reduced time to PSA biochemical recurrence (bifurcate gene expression at average, log-rank test p=0.022). Over-expression of (E) ESRP1, (F) ESRP2,
or (G) both ESRP1 and ESRP2 in PC3 cells significantly slowed the growth of prostate cancer xenografts in vivo. Data were analysed by Two-way
ANOVA, and the p value is for the overall difference between two groups.
DOI: https://doi.org/10.7554/eLife.47678.005
The following source data and figure supplements are available for figure 2:
Source data 1. Meta-analysis of 719 clinical prostate cancer tumours from 11 previously published studies detected significant up-regulation of both
ESRP1 and ESRP2 in 9/11 datasets.
DOI: https://doi.org/10.7554/eLife.47678.008
Figure supplement 1. E-Cadherin levels are not significantly increased within primary prostate tumours.
DOI: https://doi.org/10.7554/eLife.47678.006
Figure supplement 2. Ectopic expression of ESRP1 and ESRP2 protein expression in AR negative cells.
DOI: https://doi.org/10.7554/eLife.47678.007
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Figure 3. Identification of endogenous ESRP1/ESRP2 regulated target exons in prostate cancer. Heat map showing mean PSI levels for a panel of
ESRP-regulated exons in prostate cancer cell lines (CWR22RV1, PNT2, LNCaP and PC3). Mean PSIs were calculated for ESRP-regulated isoforms
between cells treated with siRNAs specific to ESRP1 and ESRP2, or control siRNAs (CWR22RV1, PNT2, LNCaP), between PC3 cells with and without
ectopic expression of ESRP1 or ESRP2, and between LNCaP cells grown in steroid deplete versus androgen stimulated conditions (10nM R1881 for 48
Figure 3 continued on next page
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the splicing switches induced by ectopic expression of either ESRP2 or ESRP1 were reciprocal to the
splicing switches detected after siRNA depletion of ESRP1/ESRP2 (Figure 3). Experimentally vali-
dated ESRP-regulated exons fell into two groups. Splicing of one group of exons were repressed by
ectopic expression of ESRP1 or ESRP2 in PC3 cells, and reciprocally activated by endogenous
ESRP1/ESRP2 depletion in LNCaP cells (these exons are in the top of the heatmap in Figure 3, from
OSBL3 to FN1). Splicing of the second group of exons were activated by ectopic expression of
ESRP1 or ESRP2, and reciprocally repressed by ESRP1/ESRP2 depletion (from TRIP10 to ITGA6 in
Figure 3).
An androgen steroid hormone-ESRP2 axis controls alternative splicing
in AR-positive prostate cancer cells
The above data identified a robust panel of alternative exons within prostate cancer cells that
responded to ESRP1/ESRP2 expression levels. We next tested if this panel of ESRP2-regulated exons
are additionally regulated by ambient androgen concentrations. LNCaP cells were harvested after
growth in steroid deplete media and after 48 hr of androgen stimulation (this timing was designed
to enable full levels of androgen-mediated ESRP2 protein induction, Figure 1H). Our prediction was
that androgen stimulation of LNCaP cells would activate ESRP2 expression to regulate our panel of
endogenous test exons. If this was the case, splicing switches in response to androgen stimulation
should occur in a reciprocal direction to splicing changes induced by ESRP1/ESRP2 protein depletion
in LNCaP cells. Consistent with these expectations, more than 70% (37/44) exons in our test panel
demonstrated androgen regulated splicing (Figure 3—source data 2). Importantly, plotting the per-
cent spliced-in (PSI) for each exon after 48 hr androgen stimulation (Y axis) versus the PSI after
ESRP1/ESRP2 depletion (X axis) showed a significant negative correlation (slope =  0.66, R2 = 0.64,
p<0.0001) (Figure 4A). Thus, exons that showed more exon skipping in response to ESRP1/ESRP2
depletion had higher splicing inclusion after androgen stimulation (which would induce ESRP2
expression) (examples shown in Figure 4A and B). Reciprocally, exons that showed higher splicing
inclusion in response to ESRP1/2 depletion also had less splicing inclusion after androgen stimulation
(examples shown in Figure 4A and C). These results experimentally support an androgen-ESRP2
axis that controls splicing patterns in prostate cancer cells.
The genes containing ESRP-activated exons that were also activated by androgen exposure
(Figure 4B) included: MINK1 (exon 18) which encodes a pro-migratory serine/threonine kinase;
MAP3K7 (exon 12) which encodes a serine/threonine kinase that regulates signalling and apoptosis,
activates NFKappaB, and is lost in aggressive prostate cancer (Kluth et al., 2013; Rodrigues et al.,
2015); GRLH1 (exon 5) that encodes a transcription factor involved in epithelial cell functions
(Jacobs et al., 2018); and FLNB (exon 30), alternative splicing of which has been identified as a key
switch contributing to breast cancer metastasis (Li et al., 2018; Ravipaty et al., 2017). Amongst the
genes containing ESRP2-repressed exons that were also skipped in response to androgen stimula-
tion (Figure 4C) were DOCK7 (exon 23), which encodes a guanine nucleotide exchange factor
involved in cell migration (Gadea and Blangy, 2014); and RPS24 (exon 5), a gene that is highly
expressed in prostate cancer (Arthurs et al., 2017).
Figure 3 continued
hr). Biological triplicate samples were used for CWR22RV1, PNT2 and LNCaP cells, and technical replicate samples were used for RNAs prepared from
PC3 cells. PSI levels were measured using RT-PCR analysis averaged from three replicates (mean data given in Figure 3—source data 2), and clustered
in the heat map according to splicing patterns across the different conditions. The heatmap was generated using heatmap.2 function using R’s ‘gplots’
package. The black shading in the heatmap denotes non-detection of the mRNA isoform after RT-PCR, and white denotes no change detected.
DOI: https://doi.org/10.7554/eLife.47678.009
The following source data is available for figure 3:
Source data 1. Alternative splicing events identified by Suppa2 (Trincado et al., 2018).
DOI: https://doi.org/10.7554/eLife.47678.010
Source data 2. Details of 44 experimentally validated ESRP1/ESRP2 target exons identified within prostate cancer cell lines.
DOI: https://doi.org/10.7554/eLife.47678.011
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Figure 4. An androgen steroid hormone-ESRP2 axis controls alternative splicing in prostate cancer cells. (A) ESRP2-regulated exons are frequently also
controlled by androgens in prostate cancer cells. 31/48 of the ESRP target exons (identified by RNAseq analysis of LNCaP cells depleted of ESRP1 and
ESRP2) were regulated in the opposite direction in LNCaP cells treated by androgens (10nM R1881) for 48 hr (which would induce ESRP2 protein
expression). Plotting the splicing responses to androgen stimulation with those after ESRP1/ESRP2 depletion revealed a negative correlation
Figure 4 continued on next page
Munkley et al. eLife 2019;8:e47678. DOI: https://doi.org/10.7554/eLife.47678 10 of 27
Research article Chromosomes and Gene Expression
The AR-ESRP2 axis controls splicing of mRNA isoforms that are
important for prostate cancer disease progression
To visualise the amplitude of ESRP2-mediated splicing control, we plotted PSIs measured in vitro
after ectopic expression of ESRP1/ESRP2 versus PSI values after siRNA mediated depletion of
ESRP1/ESRP2 (Figure 5A, using data from Figure 3 and Figure 3—source data 2, slope =  0.74,
R2 = 0.6221, p<0.0001). Consistent with the heat map (Figure 3), ESRP2-regulated exons fell into
two groups. Splicing of one group of exons were ESRP2-activated, and splicing of these were con-
versely repressed by ESRP1/ESRP2 depletion, while the second group of ESRP2-repressed exons
had the reverse properties.
To assess how important ESRP2-regulated mRNAs might be in prostate cancer we monitored
associated data for time taken to first biochemical tumour recurrence available in the TCGA PRAD
cohort, in which information for 38/44 ESRP-regulated exons was available. This analysis revealed 3
groups of ESRP-regulated exons with different clinical associations. The group of ESRP1/ESRP2-pro-
moted splice isoforms that correlated with decreased time to biochemical recurrence are shown in
black on Figure 5A (individual plots are shown in Figure 5—figure supplement 1, and the functions
of these genes and their associated splice isoforms in Figure 5—source data 1). Skipping of RPS24
exon five correlates with a worse prognosis, and is the splice isoform promoted by ESRP2. Splicing
inclusion of RPS24 exon five is needed to maintain the RPS24 open reading frame (Wang et al.,
2015). Splicing inclusion of NUMB exon three also correlated with a worse prognosis, and is acti-
vated by ESRP2. NUMB exon three encodes peptide information enabling protein interactions
between NUMB and MDM2, a protein that influence p53 stability (Colaluca et al., 2018).
Expression of the second group of ESRP1/ESRP2-promoted mRNA isoforms correlated with an
increased time to biochemical occurrence. These exons are shown in green in Figure 5A, and
include exons in the FLNB, SLK and ITGA6 genes (functions of these genes and exons are summar-
ised in Figure 5—source data 2). For example, inclusion of ITGA6 exon 25 is activated by ESRP2,
and predicted to alter signalling pathways activated by the encoded protein (Groulx et al., 2014).
Splicing inclusion of the third set of exons did not correlate with time to biochemical recurrence
(identified as grey dots in Figure 5A, and summarised in Figure 5—source data 3). These exons
included GRHL1 exon 5, splicing of which is needed to maintain the GRHL1 reading frame. GRHL1
encodes a transcription factor important for the operation of epithelial enhancer sequences
(Cieply et al., 2016; Jacobs et al., 2018).
To provide some measurement of the enrichment for clinically-relevant events, we compared the
significance of optimal biochemical reoccurrence (BCR) survival difference between ESRP-regulated
and all other exons whose PSI variance across TCGA primary tumours was 0.005 (approximately
the minimum for regulated events, to avoid biasing the potential relevance towards these). As illus-
trated in the violin plot in Figure 5D, there was a significant trend for a stronger prognostic value
amongst the ESRP-regulated exons.
Further analysis of the PRAD cohort revealed that 19/38 ESRP-regulated exons also have different
patterns of splicing inclusion between tumour and normal tissue (Figure 5E and Figure 3—source
data 2). These differentially spliced exons include the AR-ESRP2-controlled alternative exons in the
DOCK7 and RPS24 genes (both of which were excluded in prostate tumours compared to normal
prostate tissue); and the alternative exons in the MINK1 and MAP3K7 genes (each of which had
increased levels of splicing inclusion in prostate tumours compared to normal tissue). Further qRT-
Figure 4 continued
(slope =  0.66+/ 0.09, Rsquare = 0.64, p<0.0001, calculated using Graphpad). Individual values for this graph are given in Figure 3—source data 2,
and are averages from three biological replicates. (B) Capillary gel electrophoretograms showing splicing patterns of 3 biological replicates grown in
steroid deplete media, or steroid deplete media supplemented with R1881, for alternative exons that are activated by androgen exposure in the
MINK1, MAP3K1, GRHL1, FLNB, ITGA6 and NUMB genes. (C) Capillary gel electrophoretograms showing splicing patterns of 3 biological replicates
grown in steroid deplete media, or steroid deplete media supplemented with R1881, for alternative exons that are repressed by 48 hr androgen
exposure in the DOCK7, RPS24, CTNND1, FN1, MYH10 and MAGI1 genes that were repressed by four androgen treatment. For parts (B–C) the p
values were calculated using unpaired t tests, apart for CTNND1 where zero inclusion of exons 2 and 3 were detected in the presence of androgens.
For CTNND1, an RT-PCR product derived from a splice variant joining exons 1–4 via an alternative splice site is asterisked.
DOI: https://doi.org/10.7554/eLife.47678.012
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Figure 5. Alternative splicing patterns controlled by the androgen steroid hormone-ESRP2 splicing axis are clinically relevant for disease progression.
(A) Graphical representation of levels of average PSI levels in response to ectopic ESRP2 expression in PC3 cells (Y axis) versus after ESRP1/ESRP2
depletion in LNCaP cells. Individual PSI values to make this graph are averaged from three biological replicates, and are given in Figure 3—source
data 2. Note that the PSI values for ESRP over-expression refer to ESRP2 over-expression, with the exception of FNIP1 and SLC37A2 that are for ESRP1
Figure 5 continued on next page
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PCR analysis of an independent cohort confirmed more frequent skipping of DOCK7 (exon 23) and
RPS24 (exon 5) in prostate tumour tissue compared to normal prostate (Figure 5F and G).
Some exons had more subtle changes than would be apparent from just comparing overall exon
skipping and exon inclusion in prostate cancer. NUMB exon three and ITGA6 exon 25 (both acti-
vated by ESRP2) are predominantly skipped in prostate tumours compared to normal tumour tissue,
yet their PSI levels increase in larger, more advanced tumours to produce their respective mRNA iso-
forms that are associated with a decreased time to biochemical recurrence (Figure 5—figure sup-
plement 2A and B). RAC1 exon 3A (activated by ESRP2) falls into the ‘grey’ area when comparing
inclusion in normal versus prostate cancer, but more detailed analysis show that this exon is highly
included in higher Gleason grades of prostate cancer, again to produce the RAC1 splicing isoform
associated with a decreased time to biochemical recurrence (Figure 5—figure supplement 2C).
RPS24 exon 5 (repressed by ESRP2, and overall more skipped in tumours) is skipped more in larger
more advanced tumours, making the mRNA isoform associated with a decreased time to biochemi-
cal recurrence (Figure 5—figure supplement 2D). Similarly, MYO1B exon 23 (skipped in response
to ESRP2) is both overall more skipped in prostate tumour versus normal, and more skipped in
higher Gleason grade cancers (Figure 5—figure supplement 2E). FLNB exon 31 (activated by
ESRP2) actually shows slightly reduced splicing inclusion in larger, more aggressive tumours (Fig-
ure 5—figure supplement 2F).
Figure 5 continued
over-expression (see Figure 3—source data 2). Linear regression analysis of this data was analysed using Graphpad. Individual splice forms were
correlated with clinical data for time to PSA biochemical recurrence within the PRAD cohort (Saraiva-Agostinho and Barbosa-Morais, 2019). Points on
this graph corresponding to individual ESRP-regulated splice isoforms are coloured differently according to whether they correlate with an increased
time to PSA biochemical recurrence (blue dots), a decreased time to biochemical recurrence (red dots) or had no significant correlation (black dots) is
shown. (B–C) Kaplan-Meier plots showing data from TCGA PRAD cohort of percentage of tumours that are free of biochemical recurrence versus time
in years, associated with expressing the alternative splice isoforms of (B) RPS24 exon 5 (PSI cut off 0.44), and (C) FLNB exon 30 (PSI cut off 0.78)
(Saraiva-Agostinho and Barbosa-Morais, 2019). (D) Violin plots of distributions of significance of biochemical recurrence (BCR) free survival difference
between better and worse prognosis groups of patients defined by PSI cut-off values in primary tumour samples, for ESRP-regulated and all other
exons whose PSI variance across TCGA primary tumours was 0.005 (approximately the minimum for regulated events, to avoid biasing the potential
functional relevance towards these). The survival difference significance for each exon is given by -log10 of the p-value of the log-rank test used to
compare survival distributions and the PSI cut-off value is the one minimising that p-value, given by psichomics (Saraiva-Agostinho and Barbosa-
Morais, 2019).The depicted statistical significance (p) of the difference between the distributions summarised by the violins was calculated with a two-
sided Wilcoxon signed-rank test. (E) Volcano plot showing alternative splicing analysis (Saraiva-Agostinho and Barbosa-Morais, 2019) of RNAseq data
performed between normal prostate tissue and prostate tumour tissue from the TCGA PRAD cohort (consisting of 497 prostate tumour samples and 52
normal tissue). The t-test p-value (Benjamini-Hochberg adjusted for multiple testing) was used as metric of statistical significance. Significantly
differentially spliced events (|D median PSI|  0.1 and FDR  0.01) are highlighted in orange, others in grey. ESRP2-activated exons are labelled in red
text, and ESRP2-repressed exons are labelled in blue text. (F) Percentage splicing inclusion (PSI), quantified by RT-PCR, of DOCK7 exon 23 within
samples of prostate tumour and adjacent normal tissue (statistical significance calculated using t test). (G) Percentage splicing inclusion (PSI), quantified
by RT-PCR, of RPS24 exon 2 within nine matched samples of prostate tumour and adjacent normal tissue (statistical significance calculated using t test).
DOI: https://doi.org/10.7554/eLife.47678.013
The following source data and figure supplements are available for figure 5:
Source data 1. Properties of ESRP-regulated exons that correlate with a decreased time to biochemical recurrence.
DOI: https://doi.org/10.7554/eLife.47678.016
Source data 2. Properties of ESRP-regulated exons that correlate with an increased time to biochemical recurrence.
DOI: https://doi.org/10.7554/eLife.47678.017
Source data 3. Properties of ESRP-regulated exons that show no significant correlation with time to biochemical recurrence.
DOI: https://doi.org/10.7554/eLife.47678.018
Figure supplement 1. Kaplan-Meier plot showing data from TCGA PRAD cohort of percentage of tumours that are free of biochemical recurrence
versus time in years associated with expressing ESRP2-regulated alternative splice isoforms.
DOI: https://doi.org/10.7554/eLife.47678.014
Figure supplement 2. Violin plot showing PSI levels for (A) NUMB exon 6, (B) ITGA6 exon 25 (C) RAC1 exon 3A, (D) RPS24 exon 6, and (E) MYO1B
exon 23, and (F) FLNB exon 31 in different grade prostate tumours.
DOI: https://doi.org/10.7554/eLife.47678.015
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Splicing of key exons are switched by a drug that antagonises AR
activity
The above data identified a subset of ESRP2-regulated splicing switches that associated with bio-
chemical recurrence of prostate cancer after treatment. Since ESRP2 expression was repressed by
ADT in patient prostate cancer tissue, we next investigated whether AR inactivation may influence
mRNA splice isoforms that correlate with cancer progression. To test this, androgen induction of
ESRP2 mRNA expression was blocked using the androgen antagonist bicalutamide (Casodex)
(Figure 6A). Consistent with Casodex preventing expression of some potentially harmful isoforms in
prostate cancer cells, the splicing inclusion of NUMB exon three and TUFT1 exon two were reduced
by Casodex (both these exons are normally activated by androgen exposure and ESRP2). Likewise,
exon skipping events in the RPS24, FN1 and MYH10 genes that correlated with a poorer prognosis
were also reduced by Casodex (these exons are normally skipped in response to ESRP2). Not all the
splicing switches induced by Casodex correlate with increased time to biochemical recurrence. Skip-
ping of CTNND1 exon 2 and 3 correlates with a decreased time to biochemical recurrence within
the TGCA dataset (Figure 5—figure supplement 1), and this is the mRNA isoform promoted by
Casodex treatment (Figure 6C). Splicing inclusion of MAGI1 exon 7 (normally repressed by ESRP2)
and RALGPS2 exon 15 were also increased by Casodex treatment (Figure 6B and C).
ESRP2 and ESRP1 are important to maintain epithelial splicing programmes. We thus considered
whether by repressing ESRP2 expression, ADT might also inadvertently switch splicing towards mes-
enchymal patterns that could facilitate metastasis. Consistent with this prediction, treatment of
LNCaP cells with Casodex reduced splicing inclusion levels of the FLNB gene exon 30 by almost
20% (Figure 6B). Although it is not differentially spliced between normal prostate and prostate can-
cer (Figure 5E), increased skipping of FLNB exon 30 has been recently reported as a key driver of
EMT in breast cancer development (Li et al., 2018). Similarly, Casodex treatment also increased
splicing inclusion of what are normally mesenchymal-expressed exons in the CTNND1 gene
(Warzecha et al., 2009b) (Figure 6C).
We used siRNA as a further strategy to reduce AR expression (Figure 6—figure supplement 1A).
As predicted, ESRP2 protein expression was reduced by siRNA depletion of the AR (Figure 6—fig-
ure supplement 1A). Furthermore, siRNA-mediated depletion of AR reduced levels of FLNB splicing
inclusion from 84% to 69%, and levels of TUFT1 exon 2 splicing from 23% to 9% (Figure 6—figure
supplement 1B). Both these data support a scenario where splicing inclusion of ESRP2-dependent
exons are controlled by expression levels of the AR.
Splicing patterns respond to changes in the expression of ESRP2 alone
The above data suggested a model where decreases in ESRP2 expression in response to inhibition
of AR activity are sufficient to induce splicing changes, even though ESRP1 was still expressed. To
further investigate whether loss of ESRP2 alone would be sufficient to induce splicing changes we
carried out individual siRNA-mediated depletion of ESRP2 both within both LNCaP and CWR22RV1
cells. Consistent with our model, single ESRP2 depletion was able to switch splicing patterns of
exons within the MAP3K7, ARFGAP2 and CTNND1 genes (Figure 6—figure supplement 2; Fig-
ure 3—source data 2). As examples, individual depletion of ESRP2 reduced splicing inclusion of
MAP3K7 exon 12, and activated splicing inclusion of CTNND1 exons 2 and 3 (Figure 6 – Figure 3—
source data 2). Furthermore, splicing patterns of ESRP1/ESRP2 target exons were also responsive
to single up-regulation of either ESRP1 or ESRP2 (Figure 3—source data 2).
Discussion
In this study we report a novel molecular mechanism that explains how androgen steroid hormones
control splicing patterns in prostate cancer cells, and unifies the functions of the AR both as a tran-
scription factor and being able to control splicing. In this model, the AR controls expression of the
master splicing regulator protein ESRP2, which then regulates the splicing patterns of key genes
important for prostate cancer biology (Figure 7). Amongst the key data supporting this proposed
model, we find that ESRP2 is a direct and early target for transcriptional activation by the AR in pros-
tate cancer cells. Furthermore, endogenous splice isoform patterns controlled by ESRP1 and ESRP2
also respond to androgen stimulation, siRNA-mediated depletion of the AR and/or the AR inhibitor
Munkley et al. eLife 2019;8:e47678. DOI: https://doi.org/10.7554/eLife.47678 14 of 27
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Figure 6. Pharmacological inhibition of AR function switches ESRP2-dependent splicing patterns. (A) ESRP2 mRNA expression in cells grown in steroid
deplete (SD) conditions, and after addition of androgens (A+) (quantified by real-time PCR from three biological replicates). Androgen-mediated
activation of ESRP2 expression was inhibited in the presence of 10 mM of the anti-androgen bicalutamide (Casodex). Cells were cultured for 24 hr. The
p value shows the statistical significance that was calculated using a t test between the A + vehicle and the A + casodex samples. (B–C) Capillary gel
Figure 6 continued on next page
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bicalutamide (Casodex). While intuitively straightforward, this model is conceptually different from
the mechanisms through which estrogen and progesterone have been shown to regulate splicing
(via recruitment of splicing regulators as transcriptional cofactors, and by modulation of transcription
speeds and chromatin structure).
Androgens are already known to substantially modify transcriptional levels in prostate cancer,
with important implications for cell behaviour and cancer progression (Munkley et al., 2016). The
data presented here imply that androgens also have an important role in controlling splicing pat-
terns, particularly those that relate to epithelial/mesenchymal functions. Previous studies identified
just a small number of alternative exons that are controlled by androgens in prostate cancer cells,
none of which overlapped with the current study (Munkley et al., 2018; Rajan et al., 2011). We sug-
gest that an important reason for this discrepancy is because previously splicing patterns were moni-
tored after 24 hr of androgen exposure. Since we now show that splicing regulation by androgens
operates indirectly through transcriptional control of ESRP2, 24 hr androgen exposure would not be
sufficient to upregulate ESRP2 levels. In the current study we analysed androgen-dependent splicing
switches after 48 hr, to allow sufficient time for ESRP2 induction at the protein level and re-equilibra-
tion of downstream splice isoform ratios. ESRP1 expression levels also decreased in prostate
tumours following ADT so might also be under androgen-control in tissue, although did not recipro-
cally increase following androgen stimulation of cultured cells.
ESRP1 has recently been shown to be amplified in an aggressive subgroup of early onset prostate
cancer, but how this contributes to disease progression has been not well understood
(Gerhauser et al., 2018). Our data here show that ESRP1 and ESRP2 control a number of individual
mRNA splice isoforms that correlate with time to biochemical recurrence (Figure 5—figure supple-
ment 2 and Figure 5—figure supplement 1), including of MAP3K7 exon 12 inclusion which is asso-
ciated with a shorter time to biochemical reoccurrence in the TGCA database. Deletion of the
MAP3K7 gene occurs in 30–40% of prostate tumours, and is associated with a poor clinical prognosis
(Goodall et al., 2016; Kluth et al., 2013; Liu et al., 2007; Wu et al., 2012). MAP3K7 is a key gene
in prostate cancer, and MAP3K7 exon 12 splicing is associated with epithelial properties of prostate
cancer cells (Dittmar et al., 2012). More generally, epithelial splicing patterns may play an important
role early in prostate cancer development in establishing primary tumours (Figure 7).
The expression of ESRPs appears to be plastic during cancer progression (Hayakawa et al.,
2017; Ishii et al., 2014; Ueda et al., 2014). ESRPs have previously been shown to have a dual role
in carcinogenesis with both gain and loss associated with poor patient prognosis (Hayakawa et al.,
2017). ESRP1 expression is linked to poor survival and metastasis in lung cancer (Yae et al., 2012),
and both ESRP1 and ESRP2 are upregulated in oral squamous cell carcinoma relative to normal epi-
thelium (Ishii et al., 2014). Since ESRP2 is a critical component of epithelial-specific splicing pro-
grammes, we suggest that down-regulation of ESRP2 levels in response to ADT could dampen
epithelial splicing patterns, helping to prime prostate cancer cells for future mesenchymal develop-
ment and possibly contribute to development of metastasis. Supporting this, mesenchymal splicing
patterns were induced by bicalutamide (Casodex) treatment of LNCaP cells, including in the FLNB,
CTNND1 and MAP3K7 genes. FLNB encodes an actin binding protein which is linked to cancer cell
motility and invasion (Del Valle-Pe´rez et al., 2010; Iguchi et al., 2015). Skipping of FLNB exon 30 is
sufficient to initiate metastatic progression in breast cancer (Li et al., 2018). In experiments reported
here androgens promote the FLNB isoform that is not associated with metastasis. Expression of the
Figure 6 continued
electrophoretogram showing RT-PCR analysis the splicing response + /- 24 hr Casodex treatment for exons that are normally (B) activated or (C)
repressed by androgens (three biological samples shown, statistical significances were calculated using a t test, with the exception of CTNND1 where
there was zero inclusion detected for exons 2 and 3 before depletion of ESRP2, and FN1 where there was zero inclusion of exon 25 before Casodex
treatment).
DOI: https://doi.org/10.7554/eLife.47678.019
The following figure supplements are available for figure 6:
Figure supplement 1. siRNA depletion of the AR switches splicing of ESRP2- regulated exons.
DOI: https://doi.org/10.7554/eLife.47678.020
Figure supplement 2. siRNA depletion of ESRP2 alone is sufficient to switch splicing patterns of ESRP-regulated exons.
DOI: https://doi.org/10.7554/eLife.47678.021
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metastatic FLNB variant is promoted by bicalutamide (Casodex) treatment. In breast cancer, the
metastatic effects of FLNB alternative splicing are mediated via the FOXC1 transcription factor. The
role FOXC1 plays in prostate cancer progression is unknown, but FOXC1 expression may be linked
to androgen receptor levels (van der Heul-Nieuwenhuijsen et al., 2009). ESRP2 also promotes skip-
ping of epithelial-expressed exons in the CTNND1 gene (catenin delta 2, encoding a protein
involved in cell adhesion and signalling), while Casodex treatment induces expression of a normally
mesenchyme-specific splice isoform (Warzecha et al., 2009b). The Map3k12Dexon12 splice isoform
Figure 7. Model describing how exposure to androgens regulates splicing patterns in prostate cancer cells. Androgen exposure leads to transcription
of the gene encoding the master splicing regulator protein ESRP2. This promotes epithelial splicing patterns within prostate cancer cells. Lower levels
of circulating androgens after ADT lead to transcriptional repression of ESRP2. This results in a dampening of epithelial splicing patterns, and
production of normally mesenchymal splice patterns including for the FLNB, CTNND1 and MAP3K7 genes. This image was created using BioRender.
DOI: https://doi.org/10.7554/eLife.47678.022
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is produced in response to ESRP2 depletion, and is usually expressed in highly metastatic cancer cell
lines (Tripathi et al., 2019).
The clinical prognosis of metastatic prostate cancer is poor (Livermore et al., 2016). This makes
the mechanisms that control metastasis of prostate cancer cells, and any links with ADT of prime
importance. In prostate cancer EMT has been linked to a common mechanism underlying therapeu-
tic resistance and is associated with poor prognosis (Gravdal et al., 2007). Sun et al. showed that
although ADT can effectively control prostate tumour size initially, it simultaneously promotes EMT,
an unintended consequence that could ultimately lead to CRPCa (Sun et al., 2012). Such direct links
between ADT and EMT uncover an important yet overlooked consequence of the standard care
treatment for advanced prostate cancer (Byrne et al., 2016). Although the causes of EMT in pros-
tate cancer progression to CRPCa are likely to be complex, the down-regulation of ESRP proteins
has been shown to be essential for EMT progression (Horiguchi et al., 2012). Thus, loss of ESRP
expression may provide a molecular explanation why AR positive prostate cancer cells show
increased susceptibility to EMT in response to ADT, and so is relevant to consider with regard to
therapy. Our findings have important implications for second line treatment strategies in a clinical
setting, and suggest an alternative approach may be to inhibit EMT in combination with ADT to pre-
vent disease progression.
Materials and methods
Key resources table
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Gene
(H. sapiens)
ESRP1
Gene
(H. sapiens)
ESRP2
Cell line
(H. sapiens)
LNCaP ATCC CRL-1740
Cell line
(H. sapiens)
PC3 ATCC CRL-1435
Cell line
(H. sapiens)
CWR-RV1 ATCC CRL-2505
Cell line
(H. sapiens)
PNT2 Sigma Aldrich 95012613
Cell line
(H. sapiens)
RWPE-1 ATCC CRL-11609
Antibody Rabbit polyclonal
anti-ESRP2
Genetex GTX123665 1:1000 dilution
Antibody Rabbit polyclonal
anti-ESRP1
Sigma, HPA023719 1:1000 dilution
Antibody Mouse monoclonal
anti-AR
BD Bioscience, 554226 1:10000 dilution
Antibody anti-actin rabbit
polyclonal antibody
Sigma A2668 1:2000 dilution
Antibody anti-FLAG
mouse monoclonal
antibody
Sigma F3165 1:2000 dilution
Antibody normal
rabbit IgG
Jackson labs 711-035-152 1:2000 dilution
Antibody normal
mouse IgG
Jackson labs 715-036-150 1:2000 dilution
Continued on next page
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Continued
Reagent type
(species) or
resource Designation Source or reference Identifiers
Additional
information
Recombinant
DNA reagent
ESRP1
plasmid
Gift from
Prof Russ Carstens
(University of
Philadelphia. USA)
PIBX-C-FF-B-
ESRP1
Recombinant
DNA reagent
ESRP2
plasmid
Gift from
Dr Keith Brown
(University of Bristol. UK)
pBIGi hESRP2-FLAG
Sequence
based reagent
Primers to
detect splice
isoforms
This paper designed
using Primer3
http://primer3.ut.ee/
Sequence
based reagent
qPCR primers This paper designed
using Primer3
http://primer3.ut.ee/
Sequence
based reagent
siRNAs hs.Ri.ESRP1.13.1,
hs.Ri.ESRP1.13.2,
hs.Ri.ESRP2.13.1,
hs.Ri.ESRP2.13.2,
IDT (51-01-14-04),
AR esiRNA
EHU025951
Control esiRNA
EHUEGFP Sigma
Commercial
assay or kit
Rnaeasy plus kit Qiagen catalog number
74134
Commercial
assay or kit
DNA free Ambion catalog number
AM1906
Software,
algorithm
Graphpad prism https://graphpad.com
Chemical
compound, drug
synthetic
androgen analogue
methyltrienolone
(R1881)
Perkin–Elmer NLP005005MG 10 nM
Chemical
compound, drug
Bicalutamide
(Casodex)
Sigma B9061 10 mM
Cell lines and cell culture
Cell culture and androgen treatment of cells was as described previously (Munkley et al., 2015a;
Munkley et al., 2015b; Munkley et al., 2015c; Munkley et al., 2014; Rajan et al., 2011). All cells
were grown at 37˚C in 5% CO2. LNCaP cells (CRL-1740, ATCC) were maintained in RPMI-1640 with
L-Glutamine (PAA Laboratories, R15-802) supplemented with 10% Fetal Bovine Serum (FBS) (PAA
Laboratories, A15-101). For androgen treatment of LNCaP cells, medium was supplemented with
10% dextran charcoal stripped FBS (PAA Laboratories, A15-119) to produce a steroid-deplete
medium. Following culture for 72 hr, 10 nM synthetic androgen analogue methyltrienolone (R1881)
(Perkin–Elmer, NLP005005MG) was added (Androgen +) or absent (Steroid deplete) for the times
indicated. Similarly, LNCaP cells were pre-treated with with 10 mM bicalutamide (Casodex) or etha-
nol (vehicle) for 2 hr prior to addition of 10nM R1881 for 48 hr. Cell line validation was carried out
using STR profiling was according to the ATCC guidelines. All cell lines underwent regular myco-
plasma testing.
Antibodies
The following antibodies were used for western blotting: Anti-ESRP2 rabbit antibody (Genetex,
GTX123665), anti-rabbit ESRP1 (Sigma, HPA023719), anti-AR mouse antibody (BD Bioscience,
554226), anti-actin rabbit antibody (Sigma, A2668), anti-FLAG mouse monoclonal antibody (Sigma,
F3165), normal rabbit IgG (711-035-152 Jackson labs) and normal mouse IgG (715-036-150 Jackson
labs). For immunohistochemistry the following ESRP antibodies were tested: anti-rabbit ESRP1
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(Sigma, HPA023719) and anti-rabbit ESRP2 (Abcam ab113486) but were found not to be specific for
FFPE cell pellets.
RT-qPCR
Cells were harvested and total RNA extracted using TRI-reagent (Invitrogen, 15596–026), according
to the manufacturer’s instructions. RNA was treated with DNase 1 (Ambion) and cDNA was gener-
ated by reverse transcription of 500 ng of total RNA using the Superscript VILO cDNA synthesis kit
(Invitrogen, 11754–050). Quantitative PCR (qPCR) was performed in triplicate on cDNA using SYBR
Green PCR Master Mix (Invitrogen, 4309155) using the QuantStudio 7 Flex Real-Time PCR System
(Life Technologies). ESRP1 was detected using (ESRP1 for AGCACTACAGAGGCACAAACA; ESRP1
Rev TGGAGAGAAACTGGGCTACC). ESRP2 was detected using the primer combination (ESRP2 For
CCT GAA CTA CAC AGC CTA CTA CCC; ESRP2 Rev TCC TGA CTG GGA CAA CAC TG). Samples
were normalised using the average of three reference genes: GAPDH (GAPDH For AAC AGC GAC
ACC CAT CCT C; GAPDH Rev TAGCACAGCCTGGATAGCAAC); b–tubulin (TUBB For C
TTCGGCCAGATCTTCAGAC; TUBB Rev AGAGAGTGGGTCAGCTGGAA); and actin (ACTIN For CA
TCGAGCACGGCATCGTCA; ACTIN Rev TAGCACAGCCTGGATAGCAAC).
siRNA
siRNA mediated protein depletion of ESRP1/2 was carried out using Lipofectamine RNAiMAX Trans-
fection Reagent (Thermo Fisher, 13778075) as per the manufacturer’s instructions and for the times
indicated. The siRNA sequences used were ESRP1 siRNA1 (hs.Ri.ESRP1.13.1); ESRP1 siRNA2 (hs.Ri.
ESRP1.13.2); ESRP2 siRNA 1 (hs.Ri.ESRP2.13.1); ESRP2 siRNA 2 (hs.Ri.ESRP2.13.2); and a negative
control siRNA (IDT (51-01-14-04)). AR esiRNA was as described previously (Munkley et al., 2016).
Immunohistochemistry
Freshly cut tissue sections were analysed for immunoexpression using Ventana Discovery Ultra autos-
tainer (Ventana Medical Systems, Tucson, Arizona). In brief, tissue sections were incubated in Cell
conditioning solution 1 (CC1, Ventana) at 95˚C to retrieve antigenicity, followed by incubation with
respective primary antibodies described above. Bound primary antibodies were visualized using
UltraMap DAB anti-Rb Detection Kit.
AR-ChIP
LNCaP cells were stimulated with 10 nM R1881 overnight. The ChIP assay was performed using the
one step ChIP kit (Abcam ab117138) as per manufacturer’s instruction. Briefly, cells were fixed and
crosslinked in 1% formaldehyde for 10 min at 37˚C and incubated with protease inhibitors. Chroma-
tin was isolated from cell lysates and enzymatically fragmented using an EZ-Zyme Chromatin Prep
Kit (Merck 17 375). 10 ug of anti - AR antibody (Abcam ab74272) or IgG control antibody was used
to precipitate DNA crosslinked with the androgen receptor. Enriched DNA was then probed by
qPCR using primers targeting the ESRP2 regulatory region to assess AR binding intensity. Primer
sequences used to detect PSA were (PSA ChIP for GCC TGG ATC TGA GAG AGA TAT CAT C; PSA
Chip rev ACA CCT TTT TTT TTC TGG ATT GTT G). Primers used to detect AR binding near to
ESRP2 were (ESRP2 Chip for TCCCGAGTAGCTGGGACTAC; ESRP2 Chip rev CAGTGGCTTACACC
TGGGAG).
Creation of PC3 stable cell lines
The ESRP1 plasmid (PIBX-C-FF-B-ESRP1) was a gift from Prof Russ Carstens (University of Philadel-
phia. USA) and the ESRP2 plasmid (pBIGi hESRP2-FLAG) from Dr Keith Brown (University of Bristol,
UK). PC3 cells were transfected using FuGene HD Transfection Reagent as per manufacturer’s
instructions. Stable transfectants with ESRP1 was selected using 10 mg/ml Blasticidin and ESRP2 plas-
mid was selected using 150 ug/ml Hygromycin. ESRP2 Plasmid was inducible by 2.5 ug/ml doxycy-
cline for 48 hr. PC3 ESRP1 overexpressed cells were transfected with pBIGi hESRP2-FLAG plasmid
using the same protocol.
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In vitro cell proliferation analysis
For cell growth curves (carried out for in vitro analysis of PC3 stable cell lines), PC3 cells were seeded
100,000 cells per well in 12-well plate in eight plates. Cells were counted every 24 hr after seeding
in the plate. All the treatments had 12 repeats. WST assays were carried out over 7 days as per man-
ufacturer’s instructions (Cayman, CAY10008883). For DU145 cells 10,000 cells were seeded per well
in a 96 well plate. All data was tested by two-way ANOVA.
RNAseq analysis
LNCaP cells (passage 19) were treated with either control siRNAs or siRNAs targeting ESRP1 and
ESRP2 for 72 hr (samples prepared in triplicate). RNA was extracted 72 hr after siRNA treatment
using the Qiagen RNAeasy kit (Cat No. 74104) as per the manufacturer’s instructions. RNAseq was
carried out using TruSeq Stranded mRNA Sequencing NextSeq High-Output to obtain 2  75 bp
reads. Quality control of reads was performed using FastQC. Reads were mapped to the hg38 tran-
scriptome using Salmon. Differential gene expression analysis was performed using DESeq2. Percent
spliced-in (PSI) estimates for splicing events were calculated using SUPPA2 (Trincado et al., 2018)
based on isoform transcripts per million (TPM) estimates from Salmon (Patro et al., 2017). Quantifi-
cation utilised Gencode gene models (release 28). Differential PSI was calculated using DiffSplice
using the empirical method (Hu et al., 2013). Events with a delta PSI > 10% and FDR < 0.05 were
considered as significant.
Psichomics and bioinformatic analysis of PRAD cohort
Clinical expression patterns of ESRP2-regulated exons were monitored using psichomics (Saraiva-
Agostinho and Barbosa-Morais, 2019). Differential splicing analysis between primary solid tumour
and solid tissue normal samples were subsequently performed to evaluate relative higher inclusion
levels in either tumour or normal tissue samples using D median and t-test p-value (Benjamini-Hoch-
berg adjusted) values. Survival analysis based on TCGA clinical data derived from prostate cancer
patient samples was performed with time to first PSA biochemical recurrence being the event of
interest. Additional statistical analyses and generation of plots were performed in R
(R Development Core Team, 2019). Violin plots were created with R package vioplot (Adler and
Kelly, 2018).
Tumour xenografts
Stable overexpression of ESRP1 and stable doxycycline-inducible overexpression of either ESRP2
alone or ESRP1 and 2 were obtained using PC3 cells (that have the low endogenous levels of both
proteins). One million PC3 overexpressing ESRP1 or control cells were injected subcutaneously in
the flank of male nude mice and tumour volumes were monitored. Two million PC3 cells overex-
pressing ESRP2, overexpressing ESRP1 and 2, or control cells were injected subcutaneously in the
flank of male nude mice and tumour volumes were monitored. PC3 ESRP2 and PC3 ESRP1/2 cells
were cultured in medium supplemented with 2.5 ug/ml doxycycline for 48 hr prior to injecting into
nude mice to induce ESRP2 expression and mice were administered Doxycycline repeatedly. Tumour
diameters were measured using calipers.
Clinical samples
Our study made use of RNA from 32 benign samples from patients with benign prostatic hyperplasia
(BPH) and 17 malignant samples from transurethral resection of the prostate (TURP) samples. Malig-
nant status and Gleason score were obtained for these patients by histological analysis. We also ana-
lysed normal and matched PCa tissue from nine patients obtained by radical prostectomy. The
samples were obtained with ethical approval through the Exeter NIHR Clinical Research Facility tis-
sue bank (Ref: STB20). Written informed consent for the use of surgically obtained tissue was pro-
vided by all patients. The RNA samples analysed in Figure 2C were previously published
(Walker et al., 2017).
Statistical analyses
All statistical analyses were performed using GraphPad Prism 6 (GraphPad Software, Inc). Statistical
analyses were conducted using the GraphPad Prism software (version 5.04/d). PCR quantification of
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mRNA isoforms was assessed using the unpaired student’s t-test. Data are presented as the mean of
three independent samples ± standard error of the mean (SEM). Statistical significance is denoted as
*p<0.05, **p<0.01, ***p<0.001 and ****p<0.0001.
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